Financial Performance
Vijaya Diagnostic reported a robust financial year ending March 2026, with Profit After Tax (PAT) increasing 20.3% to ₹1,730 million. The company's fourth-quarter performance was particularly strong, with revenue growing 26.6% year-on-year. This growth was driven by a mix of volume increases and higher realizations, as the revenue per test rose to ₹481.
The company maintained a healthy revenue mix, with pathology contributing 63% and radiology accounting for 37% of the total turnover. Operating cash flows remained strong at ₹224.47 crore for the annual period.
Management Outlook
Management expressed high confidence in the brand's acceptance across new markets, specifically citing disciplined execution in the West Bengal and Pune regions. For FY27, the focus remains on deepening the network in South India while scaling integrated diagnostic hubs in newer geographies. The company plans to upgrade its central laboratory in Hyderabad with full automation and launch advanced genomic testing services.
Long-term guidance suggests a steady growth trajectory of approximately 15%, though the company achieved a higher CAGR of 16.5% over the last five years.
Business Overview
Vijaya Diagnostic Centre Limited is a leading integrated diagnostic chain in India, primarily dominant in South India. It offers a comprehensive range of services covering both pathology and radiology under one roof. The company operates a hub-and-spoke model, which facilitates efficient sample processing and high-end imaging services.
Recent strategic moves include the consolidation of Medinova and PH Pune acquisitions, which have helped the company expand its footprint outside its home markets of Telangana and Andhra Pradesh.
Sector Dynamics
The diagnostic sector is witnessing a shift towards organized players as quality and reliability become paramount for patients. Management noted that while pricing competition remains a factor in the pathology segment, the integrated model providing both radiology and pathology offers a competitive moat. The rapid growth in the wellness and preventive healthcare segment indicates a structural change in consumer behavior post-pandemic.
Vijaya's ability to maintain industry-leading EBITDA margins above 40% highlights its operational efficiency amidst rising costs and competitive intensity in the broader healthcare services industry.
What to Watch
- Execution and break-even timelines for the newly planned hubs in West Bengal and Pune markets.
- Sustainability of the 41%+ EBITDA margins in an increasingly competitive pricing environment.
- Contribution of advanced genomic testing and automated lab upgrades to overall revenue per test.
- Integration progress and margin accretion from recent inorganic acquisitions including Medinova.
